OxyContin’s 1996 launch marks an important point of reference in the book’s account of the American opioid crisis: a prescription painkiller entered a system in which opioid supply would expand, economic security would erode, and many people dependent on pills would later turn to heroin. The account does not treat the launch as a self-contained episode. Its significance emerges over the years that followed, in the routes by which addiction spread and in the unequal institutions that responded to it.

Launch and the Expanding Prescription Supply

The book places OxyContin’s introduction within a broader rise in opioid availability. It describes a crisis shaped by painkillers promoted by pharmaceutical companies and by regulators approving one opioid medication after another. The launch therefore stands within an expanding supply environment, rather than as an isolated explanation for the epidemic that followed.

The chronology gives the drug’s introduction a long reach. Purdue Pharma launched an abuse-resistant version in 2010, fourteen years after OxyContin was introduced. By then, the epidemic had moved beyond the settings in which heroin had once been most visible. In Roanoke, heroin had commonly been regarded as an inner-city drug, and its users as a relatively small, largely unseen group. Later, opioid use appeared in affluent suburbs as well as elsewhere, changing the public understanding of who was at risk.

From Pills to Heroin

The book describes a recurring path from prescription opioids to heroin: some users began with pills, then bought heroin and sold part of what they had acquired to finance their next purchase. Dependence made avoiding withdrawal an urgent priority, while recruiting new buyers could extend the cycle. This pattern connects the prescription era to later heroin markets without reducing the transition to a single cause or moment.

In Roanoke’s suburbs, opioid use moved through peer groups. The book contrasts that route with an earlier public image of heroin as confined to an isolated, predominantly Black population. The changing pattern became visible to police only around the time Purdue Pharma introduced its abuse-resistant formulation in 2010. The juxtaposition underscores a distinction between when a problem becomes institutionally noticeable and how long its conditions have been developing.

Structural Conditions and Unequal Responses

The account identifies the collapse of work, rising disability, and the flood of painkillers as elements of the crisis’s wider conditions. Economic decline was not limited to rural areas, though it was less severe in places with more physicians who prescribed fewer opioids and higher proportions of college graduates. In this analysis, the launch belongs to a story about both drug availability and the social circumstances that shaped exposure and vulnerability.

Medical and criminal-justice institutions did not distribute their responses evenly. The book reports that physicians prescribed painkillers to people of color at substantially lower rates than to white patients, amid distrust rooted in racial stereotyping. At the same time, people of color were disproportionately represented among drug offenders facing imprisonment. The account sets these patterns beside calls to treat addiction as a public-health problem, noting that such calls were more readily applied to predominantly white opioid users than to people imprisoned for heroin distribution.

Lasting Significance

By linking OxyContin’s introduction to later movement from pills to heroin, the book makes the launch a point in a longer chain of consequences rather than a complete explanation for them. The chain runs through expanding supply, peer networks, economic distress, and gaps between health care and criminal justice. Its significance lies in how these forces interacted—and in how the resulting crisis could remain hidden until it reached communities that institutions and news coverage had not previously treated as its likely center.